Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity

Mengrui Liu,Shiqi Hu,Na Yan,Kristen D. Popowski,Ke Cheng
DOI: https://doi.org/10.1038/s41565-023-01580-3
IF: 38.3
2024-01-12
Nature Nanotechnology
Abstract:Lung carcinoma is one of the most common cancers and has one of the lowest survival rates in the world. Cytokines such as interleukin-12 (IL-12) have demonstrated considerable potential as robust tumour suppressors. However, their applications are limited due to off-target toxicity. Here we report on a strategy involving the inhalation of IL-12 messenger RNA, encapsulated within extracellular vesicles. Inhalation and preferential uptake by cancer cells results in targeted delivery and fewer systemic side effects. The IL-12 messenger RNA generates interferon-γ production in both innate and adaptive immune-cell populations. This activation consequently incites an intense activation state in the tumour microenvironment and augments its immunogenicity. The increased immune response results in the expansion of tumour cytotoxic immune effector cells, the formation of immune memory, improved antigen presentation and tumour-specific T cell priming. The strategy is demonstrated against primary neoplastic lesions and provides profound protection against subsequent tumour rechallenge. This shows the potential for locally delivered cytokine-based immunotherapies to address orthotopic and metastatic lung tumours.
materials science, multidisciplinary,nanoscience & nanotechnology
What problem does this paper attempt to address?
The main problems that this paper attempts to solve are two key challenges in lung cancer treatment: one is how to effectively deliver cytokines (such as IL - 12) to inhibit tumor growth, and the other is how to reduce systemic side effects and improve the safety and effectiveness of immunotherapy. Specifically, the paper explores a method of encapsulating IL - 12 mRNA in extracellular vesicles (EVs) and directly delivering it to the lung tumor microenvironment (TME) through the inhalation route. This method aims to achieve a high - concentration local expression of IL - 12 while reducing systemic toxic side effects. ### Main research contents: 1. **Background and motivation**: - Lung cancer is one of the most common cancers with a relatively low survival rate. - Cytokines such as IL - 12 have significant anti - tumor potential, but there is serious off - target toxicity when applied systemically. - Although traditional cytokine delivery methods (such as liposomes) can deliver locally, there are still certain toxicity and off - target effects. 2. **Research methods**: - **Preparation and characterization**: Use electroporation technology to load IL - 12 mRNA into exosomes derived from human embryonic kidney cells (HEK - Exo) to prepare IL - 12 - Exo. - **Delivery method**: Deliver IL - 12 - Exo to the lungs of mice by nebulized inhalation. - **In - vivo distribution and cell uptake**: Evaluate the distribution of IL - 12 - Exo in the lungs and its uptake by tumor cells and other immune cells. - **Anti - tumor effect**: Evaluate the anti - tumor effect of IL - 12 - Exo in the LL/2 lung cancer allograft model, including indicators such as tumor growth inhibition, body weight change, and survival rate. - **Immunomodulatory effect**: Analyze the activation effect of IL - 12 - Exo on immune cells in the tumor microenvironment, especially the production of IFNγ and its impact on immune cells. 3. **Main findings**: - **Local delivery**: IL - 12 - Exo can be effectively enriched in the lung tumor microenvironment, reducing its distribution in other organs, thereby reducing systemic toxicity. - **Anti - tumor effect**: IL - 12 - Exo significantly inhibits the growth of lung tumors, prolongs the survival period of mice, and there is no obvious body weight loss. - **Immune activation**: IL - 12 - Exo promotes the production of IFNγ, enhances the infiltration of immune cells such as CD8+ T cells, CD4+ T cells, and NK cells, and reduces the number of immunosuppressive cells (such as Treg cells and MDSCs). - **Long - term protection**: Mice treated with IL - 12 - Exo show stronger resistance to subsequent tumor rechallenge. ### Conclusion: This study has successfully developed an extracellular vesicle system for delivering IL - 12 mRNA through the inhalation route, which can achieve a high - concentration local expression of IL - 12 in the lung tumor microenvironment, effectively inhibit tumor growth, and enhance the systemic immune response while significantly reducing systemic toxicity. This strategy provides new ideas and methods for the treatment of lung cancer and other lung diseases.